Bend BioScience

Articles

Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras –
a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.

Molecular Properties of PROTACs and the Relationship to Formulation Design

A case study in converting a solution formulation of a protein into an oral solid dosage form utilizing a fluid bed granulation process and some of the complexities involved.

Development Process for Transforming a Liquid Protein Solution into a Solid Oral Dosage Form

, industry experts discuss their experiences in dealing with the challenges of developing and manufacturing next-generation biotherapeutics. They also discuss their triumphs in creating innovations to move the industry as a whole forward.

https://www.pharmtech.com/pt_w/challenges-and-triumphs

The development of next-generation biotherapeutics is in full swing, which means that developers and biomanufacturers are tackling new challenges in the drug development and manufacturing lifecycle. Two areas of focus are in the maintenance of an aseptic environment throughout the manufacturing process and the search for solutions to establishing alternative drug delivery methods that don’t require a parenteral route of administration. In this episode of 

, experts from N4 Pharma and Cellular Origins discuss their experiences in dealing with these challenges, as well as triumphs in creating innovations to move the industry as a whole forward.
Interviews featuring:

Dan Strange, PhD, Chief Technology Officer, Cellular Origins

This episode of Drug Digest is sponsored by:

Progress made in alternative drug delivery for biologics

Learn about innovative platform technologies

Insight into automation technologies in aseptic processing

Where the industry sees the next big biologic “breakthrough”

Formulation & drug delivery scientists/technicians

Biotechs involved in next-gen technologies/biomolecule development


CEO
N4 Pharma

Nigel Theobald is CEO of N4 Pharma, a specialist pharmaceutical company developing novel delivery systems for oncology, gene therapy and vaccines. Theobald has over 25 years’ experience in healthcare, in building businesses, strategy development and implementation, and in a strong network covering all aspects of pharmaceutical product development and commercialization. He was the head of healthcare brands at Boots Group plc in 2002 before leaving to set up a series of successful businesses, including Oxford Pharmascience Group plc, which he grew over five years into an AIM-quoted company with a market capitalization of £40 million (US$53 million) upon departure. Theobald formed N4 Pharma in 2014.




Chief Technology Officer
Cellular Origins

Dan Strange has been working at the intersection of engineering and biology for almost 15 years, and he is an inventor on 20 patents. After completing a PhD in regenerative medicine at the University of Cambridge, he moved to TTP where he developed complex drug delivery devices. He was instrumental in the creation of multiple technology platforms successfully licensed to large pharma in deals worth over $100 million. For the past four years, Strange has focused on cell therapy manufacturing equipment. Strange is an active member of various automation working groups and was a reviewer on the Alliance for Regenerative Medicines A-Cell report on cell therapy manufacturing.

Webcasts

Webinar Date/Time: Fri, Dec 13, 2024 11:00 AM EST
